Does whole genome sequencing circumvent gene patents?


 What happens when, during the course of whole-genome sequencing (WGS) a patient or research subject, an investigator sequences and analyzes a disease gene that has been patented? The U.S. Supreme Court will shed some light on this question next year when it issues its ruling in the long-running Myriad Genetics saga. 

View the original article here: Does Whole Genome Sequencing Circumvent Gene Patents?